Alkermes plc ALKS announced the initiation of the phase II Vibrance-2 study, evaluating its novel, investigational, oral orexin 2 receptor agonist ALKS 2680 in adults with narcolepsy type 2 (NT2). The ...

– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – – Alixorexton ...

People with certain types of long-term sleep disorders may use a medicine called sodium oxybate to help treat their condition. This medicine is taken at night and may help people with narcolepsy to ...

ZURICH, SWITZERLAND / ACCESSWIRE / January 30, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the ...

People with narcolepsy often need to take medicines to manage their symptoms. Many of these medicines carry a high risk for abuse or misuse, so there are restrictions on how they are prescribed and ...

SAN DIEGO — The investigational drug AXS-12 (reboxetine, Axsome Therapeutics) is safe and effective for the treatment of cataplexy (emotionally induced muscle weakness) and excessive daytime ...

The high prevalence of anxiety and depression in patients with narcolepsy suggests that a biological relationship is present between the disorders, but larger studies are needed. Sleep disorders are ...

Recognizing markers like atonia index during wakefulness (WAI) that are not present in other hypersomnias might help in the diagnosis of narcolepsy. Atonia index during wakefulness (WAI) might ...

A new study has demonstrated a new way to treat narcolepsy-related nightmares. The scientists combined cognitive behavioral therapy (CBT) and lucid dreaming to help patients in a small clinical trial.

– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the ...